Videos

Paul G. Richardson, MD, clinical program leader and director of Clinical Research in the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute, discusses results from the phase III OPTIMISMM trial comparing treatment regimens for relapsed/refractory multiple myeloma. This data compares a regimen of pomalidomide, bortezomib, and dexamethasone versus bortezomib and dexamethasone alone. 

Ami V. Desai, MD, MSCE, assistant professor of Pediatrics at the University of Chicago Medicine Comer Children’s Hospital, discusses the current treatment landscape for pediatric and young adult patients with relapsed/refractory solid tumors.

Breast Cancer

Thierry Andre, MD, professor of medical oncology at the University Pierre et Marie Curie (UMPC) and Head of the Medical Oncology Department in St. Antoine Hospital, Assistance Publique Hôpitaux in Paris, discusses the introduction of immunotherapy to the treatment landscape of metastatic colorectal cancer.

W. K. Alfred Yung, MD, a professor of Neuro-oncology at MD Anderson Cancer Center, discusses the future of immuno-oncology in the treatment landscape of brain cancer. 

Treating AML With Myelodysplasia-Related Changes

Treatment Options and Care for Patients Who Develop Therapy-Related AML

Martin Hutchings, MD, PhD, senior consultant in the Department of Hematology at the Copenhagen University Hospital, discusses common implications in treating patients with advanced stage Hodgkin lymphoma. Trials rarely perform subgroup analyses, and when they do, it is common for researchers to come across particular biases in the selected subgroups.